Country: Canada
Language: English
Source: Health Canada
RANITIDINE (RANITIDINE HYDROCHLORIDE)
APOTEX INC
A02BA02
RANITIDINE
150MG
TABLET
RANITIDINE (RANITIDINE HYDROCHLORIDE) 150MG
ORAL
24
OTC
HISTAMINE H2-ANTAGONISTS
Active ingredient group (AIG) number: 0115150002; AHFS:
APPROVED
2007-06-06
Page 1 of 33 PRODUCT MONOGRAPH ACID REDUCER Ranitidine Tablets USP 75 mg and 150 mg Ranitidine (as Ranitidine Hydrochloride) Histamine H 2 -receptor antagonist APOTEX INC., Date of Revision: 150 Signet Drive January 24, 2020 Toronto, Ontario M9L 1T9 Submission Control No.: 238800 Page 2 of 33 TABLE OF CONTENTS _ _ PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE ................................................................................. 3 CONTRAINDICATIONS ....................................................................................................... 3 WARNINGS AND PRECAUTIONS ..................................................................................... 4 ADVERSE REACTIONS ....................................................................................................... 5 DRUG INTERACTIONS ........................................................................................................ 7 DOSAGE AND ADMINISTRATION ................................................................................... 9 OVERDOSAGE .................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY ................................................................ 10 STORAGE AND STABILITY .............................................................................................. 15 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 15 PART II: SCIENTIFIC INFORMATION .................................................................................. 17 PHARMACEUTICAL INFORMATION ............................................................................. 17 DETAILED PHARMACOLOGY ......................................................................................... 18 TOXICOLOGY ............. Read the complete document